1428077-72-8

Basic information

• Product Name: (4S,4aR,7aR)-6,6-difluoro-4-fluoromethyl-4-(2-fluoro-5-nitro-phenyl)-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine
• Synonyms: (4S,4aR,7aR)-6,6-difluoro-4-fluoromethyl-4-(2-fluoro-5-nitro-phenyl)-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine
• CAS NO: 1428077-72-8
• Molecular Weight: 347.269
• Mol File: 1428077-72-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (4S,4aR,7aR)-6,6-difluoro-4-fluoromethyl-4-(2-fluoro-5-nitro-phenyl)-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (4S,4aR,7aR)-6,6-difluoro-4-fluoromethyl-4-(2-fluoro-5-nitro-phenyl)-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine(1428077-72-8)
• EPA Substance Registry System: (4S,4aR,7aR)-6,6-difluoro-4-fluoromethyl-4-(2-fluoro-5-nitro-phenyl)-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine(1428077-72-8)

Safety Data

• Hazardous Substances Data: 1428077-72-8(Hazardous Substances Data)

Upstream product

• 1428078-57-2 (3S,3aR,6aR)-5,5-difluoro-3-fluoromethyl-3-(2-fluoro-phenyl)-hexahydro-cyclopenta[d]isoxazole 
• 1428077-58-0 rac-(3aR,6aR)-5,5-difluoro-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]isoxazole-3-carboxylic acid ethyl ester 
• 1428077-54-6 rac-(3aR,6aR)-5-oxo-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]isoxazole-3-carboxylic acid ethyl ester 
• 1428077-69-3 (4S,4aR,7aR)-6,6-difluoro-4-fluoromethyl-4-(2-fluoro-phenyl)-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine 
• 1428077-66-0 (1R,2R)-2-[(S)-1-amino-2-fluoro-1-(2-fluoro-phenyl)-ethyl]-4,4-difluoro-cyclopentanol 
• 14320-37-7 3-Cyclopentenon 

Downstream Products

• 1428077-75-1 (4S,4aR,7aR)-4-(5-amino-2-fluoro-phenyl)-6,6-difluoro-4-fluoromethyl-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-2-ylamine 

Relevant articles and documents

N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS

The present invention provides N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.